for Growth

1. IR Presentation for Growth

2. NEW Run for Growth This IR Presentation contains forward-looking statements that involve risks and uncertainties. The actual results may differ from those we project and may be affected by business environment, government regulation and legislation, financial market movement, etc.

3. LG Life Sciences… • Products Line-up • R&D Activities • Core Values

4. History & Growth Pathway Global Company Gearing-up Building-up 2011 NCE Research Bio Research 2006 2002 1994 1983 • Pharmaceutical business initiated • NCE Research • Stabilizing operation • Critical mass • Global market presence • World-class performance Target • Bio research • Acquired AN-JIN Pharm corp. • Strategic alliance • Euvax B, Eutropin • Zanidip, Eutropin • Out-licensing • R&D productivity • Sales efficiency • Global products • Innovative R&D Growth Driver • First launch of bio-pharmaceuticals in Korea (Interferon, hGH) • Factive, out-licensed to SB • Strategic alliance with BioPartners • Factive, approved from US FDA • Marketing alliance with Novartis(Korea) • Caspase inhibitor, out-licensed to Gilead Milestone

5. Business Activities - Domestic Seoul •  Head Office: Seoul • R&D Center: Daejeon • Plants : Iksan (Pharmaceuticals, rBST) Onsan (API, Agrochemicals) • Sales Offices : 11 major cities • Total Personnel : 1,100 (R&D 30%, Sales 30% Manufacturing 30%) Daejeon Onsan Iksan

6. Business Activities - Overseas • LGLSI(India) Personnel : 130 • China Branch Personnel : 3 • Global Alliances • Total 25 Products • Euvax B • Valtropin • Factive • Factive • Insecticide • Infertility • Euvax B • Eutropin • Espogen • Factive North America (11%) EU (7%) • Euvax B • Factive • Insecticide • Boostin • Espogen • Others Middle East (11%) Africa (4%) • Boostin • Euvax B • Eutropin • Espogen • Factive • Insecticide • Euvax B • Boostin • Espogen • Infertility South America (29%) Asia (36%) 2007 Overseas Sales ($80M, 36%)

7. Business Results Annual Results (Bil KRW) Quarterly Results(Bil KRW) Sales(royalties) Operating Income Sales(royalties) Operating Income (24.1) (20.6) (3.4) (20.2) (8.5) (1.2) (1.3) (20.1) (2.0) (0.1)

8. LG Life Sciences… • Products Line-up • R&D Activities • Core Values

9. Euvax B Zanidip Eutropin Others Factive Hyruan Plus 20 15 10 5 1 In-house L/I ’02 ’04 ’06 ‘08 ’10 Products Line-up Newly Defined Therapeutic Areas Market & Customer (Mega-trend) Ex-product Portfolio • Undefined TA (therapeutic area) • Product-centered approach • In-house R&D interest Chronic Disease Slide 10 Aging Society Well-being Slide 11 Income Level Improvement New Approach Number of products • Clearly defined TA(therapeutic area) • Product line-up based on newly defined TA • Market & Customer friendly Increased Need for Preventive Healthcare Preventive Healthcare Slide 12 Others Co-Marketing

10. Chronic Disease • CCB : Calcium Channel Blocker • ARB : Angiotensin Ⅱ Receptor Blocker

11. Well-being • GHD : Growth Hormone Deficiency • IVF-M : HMG (human menopausal gonadotropin) • IVF-C : HCG (human chorionic gonadotropin) • ART : Assistant Reproductive Technology

12. Preventive Healthcare Vaccines Diagnostics • ELISA : Enzyme-linked Immunosorbent Assay, - POCT : Point-of-care Testing • real time PCR : Polymerase Chain Reaction

13. API Business FactiveTM • Quinolone antibioticfor respiratory tract infection • 1st US FDA-approved drug in Korea • Indication - 5-dayCAP, AECB, ABS - Excellent efficacy, better patient compliance • Globalization - US : Launched in Sep. 2004 (Oscient) - Mexico (Pfizer), Canada (Abbott), EU (Menarini) : Sub-licensed by Oscient - Russia, South Africa, China, Brazil, Turkey, Middle East, etc. : Launching CMO Business (Bil KRW) • CAP : Community Acquired Pneumonia, - AECB : Acute Exacerbations of Chronic Bronchitis • ABS : Acute Bacterial Sinusitis, - CMO : Contract Manufacturing Organization

14. LG Life Sciences… • Products Line-up • R&D Activities • Core Values

15. PhaseⅡ/Ⅲ, Approval Target Candidate, Pre/PhaseⅠ Alliance / Outsourcing Enhancing R&D productivity Focused R&D (Outside-In) Risk Management (Open Innovation) • Growth • Anti-aging • Infertility • Obesity • Value Creation Competitiv-eness Well-being Global Pharma Market & Customer (Mega-trend) Chronic Disease Out-licensing / Co-development Preventive Healthcare • Cardiovascular • Diabetes • Liver disease • Degenerative • arthritis Cost • Combo-vaccine • Diagnostics

16. R&D Pipeline – New Chemical Entities • HBV : Hepatitis B Virus • DPP-IV : Dipeptidyl Peptidase IV • ROW : Rest Of The World

17. R&D Pipeline – Biologics • DTaP : Diphtheria, Tetanus toxoids, acellular(whole cell) Pertussis adsorbed • ROW : Rest Of The World

18. NEW Run for Growth • LG Life Sciences… • Products Line-up • R&D Activities • Core Values

19. LG Way LG’s vision is to become the best in its class By winning customer’s acclaim as a leader in the global market Vision No.1 LG “Jeong-Do” Management is LG’s unique code of conduct that governs our management activities. The English translation of “Jeong-Do” is “the right way”. “Jeong-Do” Management Code of Conduct - LG provides equal opportunities for its employees - LG rewards its employees based on their capabilities and performance - LG serves customers with integrity - LG strives to build competence through innovation Respecting Human dignity Creating value for customers Managemnet Principles